VRXA — Veraxa Biotech AG - Post de-SPAC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2079109 · Switzerland
Last close
$1.04
Market Cap
$147.06M
52W High
$27.36
52W Low
$0.90
ADV30
251,121
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Dec 2025 — — — — 80,820,364 1,613,989 96,586,511
Jun 2025 — — — — 82,248,288 3,315,409 69,521,680

Balance + Analyst (yfinance extras)

Retained Earnings
$-98,478,340
Inventory
—
Receivables
$1,170,351
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$23,426
EBITDA
$-64,244,176
Free Cash Flow
$15,751,170
Enterprise Value
—
Total Cash
—
Total Debt
—
Shares Out
141,407,813
Trailing EPS
$-0.58
Book Value
$-1.31
ROE
-871.4%
ROA
-50.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 23,426 -66,216,575 -66,613,990 80,820,364 96,586,511 -15,766,147 -9,902,331
Dec 2024 0 -28,917,881 -28,132,971 84,766,624 53,711,808 31,054,816 -7,720,393
Dec 2023 0 -16,659,993 -16,544,238 91,936,907 36,809,163 55,127,744 -7,267,818

Peers — same industry

TickerNameMarket CapLastDaily %
ZNTL Zentalis Pharmaceuticals, Inc. $146.42M $1.49 —
RNA Atrium Therapeutics, Inc. $139.78M $6.48 —
ALXO ALX ONCOLOGY HOLDINGS INC $138.97M $1.00 —
BBOT BridgeBio Oncology Therapeutics, Inc. $155.69M $1.94 —
SION Sionna Therapeutics, Inc. $138.87M $3.07 —

News headlines (Yahoo Finance, 1h cache)

VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
2026-09-22 18:30 · Yahoo
VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline
2026-10-21 19:00 · Yahoo
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
2026-10-13 19:30 · Yahoo
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
2026-10-13 11:00 · Yahoo
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
2026-10-07 19:00 · Yahoo
This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
2026-10-07 13:58 · Yahoo
Veraxa Biotech stock gains on FDA-aligned testing strategy
2026-10-07 13:29 · Yahoo
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
2026-10-07 11:00 · Yahoo
VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
2026-09-24 19:38 · Yahoo
VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
2026-09-18 19:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.